| Literature DB >> 31544536 |
Eli Muchtar1, Angela Dispenzieri1, Dragan Jevremovic2, David Dingli1, Francis K Buadi1, Martha Q Lacy1, Wilson Gonsalves1, Rahma Warsame1, Taxiarchis V Kourelis1, Suzanne R Hayman1, Prashant Kapoor1, Nelson Leung1,3, Stephen Russell1, John A Lust1, Yi Lin1, Ronald S Go1, Steven Zeldenrust1, Robert A Kyle1, S Vincent Rajkumar1, Shaji K Kumar1, Morie A Gertz1.
Abstract
Response assessment in light chain (AL) amyloidosis is challenging given the low level of circulating free light chains usually seen. Multi-parametric flow cytometry (MFC) from a marrow aspirate was demonstrated to retain a prognostic significance in several recent studies. In this work, 82 AL patients who had MFC study at end of therapy were analysed based on whether clonal plasma cells were detected or not. Among patients who achieved deep response (i.e. very good partial response or complete response) to first-line therapy, lack of clonal marrow plasma cells as measured by MFC was associated with improved progression-free survival (PFS) compared to patients with residual clonal plasma cells (3-year PFS 88% vs. 46%, p = .003), particularly among patients who achieved a complete response (3-year PFS 100% vs. 33%, p = .001). Absence of clonal plasma cells by MFC compared with patients with detectable clonal plasma cells among deep responders was associated with lower level of involved light chain (involved free light chain (iFLC), median 1.1 vs. 1.7 mg/dL; p = .02) and higher frequency of renal response (100% vs. 68%; p = .005). Further studies are needed to determine if MFC should be incorporated into response criteria in AL amyloidosis.Entities:
Keywords: Flow cytometry; light chain; minimal residual disease; response; survival
Year: 2019 PMID: 31544536 DOI: 10.1080/13506129.2019.1666709
Source DB: PubMed Journal: Amyloid ISSN: 1350-6129 Impact factor: 7.141